We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after February 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Crystal forms of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide and methods for their preparation
CRYSTALLINE FORMS OF AFATINIB DI-MALEATE
Crystalline raltegravir sodium salts
Crystalline salts of sitagliptin
MICRORNAS AND CELLULAR REPROGRAMMING
NOVEL CATIONIC POLYPHOSPHAZENE COMPOUND, POLYPHOSPHAZENES-DRUG CONJUGATE COMPOUND AND METHOD FOR PREPARING SAME
SPRAY-FREEZE DRYING OF POLYELECTROLYTE NANOPARTICLES CONTAINING THE PROTEIN DRUG
DIPHENETHYLAMINE DERIVATIVES WHICH ARE INTER ALIA USEFUL AS ANALGESICS AND METHODS FOR THEIR PRODUCTION